An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain Barré syndrome

Neurology India

Volumn 57, Issue 3, 2009, Pages 288-294

  Gonzalez Quevedo, A ^a,b   Carriera, R ^a   O'Farrill, Z ^a   Luis, I ^a   Becquer, R ^a   Luis Gonzalez, R ^a  

^a INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA   (Cuba)

^b NONE   (Cuba)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Guillain Barr syndrome

Indexed keywords

PREALBUMIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CHILD; DISEASE SEVERITY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHOOL CHILD;

ADOLESCENT; ADULT; BLOOD-BRAIN BARRIER; CEREBROSPINAL FLUID PROTEINS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; PREALBUMIN; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 67651160570     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.53282     Document Type: Article

References (31)

1. Hughes RAC, Cornblath DR. Guillain-Barré Syndrome. Lancet 2005;366:1653-1656
2. Hartung, HP Willison, HJ. Kieseier, BC. Acute immunoinflammatory neuropathy: Update on Guillain-Barré síndrome. Curr Opin Neurol 2002;15:571-577
3. Owen B. Evans and Vettaikorumakankav Vedanarayanan. Guillain- Barré Síndrome. Pediatr Rev 1997;18:10-16
4. Deisenhammer F, A. Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, Sellebjerg F. Guidelines on routine cerebrospinal fluid analysis: Report from an EFNS task force. Eur J Neurol 2006;13:913-922 (Pubitemid 44284895)
5. Winer JB. Guillain Barré syndrome. J Clin Pathol Mol Pathol 2001;54:381-385
6. Kieseiera BC, Hartunga HP, Wiendl H. Immune circuitry in the peripheral nervous system. Curr Opin Neurol 2006;19:437-445 (Pubitemid 44395264)
7. Hadden RDM, Gregson NA, Gold R, Smith KJ, Hughes RAC. Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol and Appl Neurobiol 2002;28:489-497
8. Byun WM, Park WK, Park BH, Ahn SH, Hwang MS, Chang JC. Guillain-Barre syndrome: MR imaging findings of the spine in eight patients. Radiology 1998;208:137-141 (Pubitemid 28323321)
9. National Institute of Neurological and Communicative Disorders and Stroke Ad Hoc Committee. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565-566
10. Estrada Gonzalez R, Gonzalez Pal S. Tratamiento de la polirradiculoneuritis aguda tipo Landry-Guillain-Barre-Strohl con betametasona intrafecal. Rev Cub Invest Biomed 1982;1:57-64.
11. Lowry OH, Rosebrugh RJ, Farr AI, Randal RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-275
12. Smith I. Chromatographic and electrophoretic techniques. Vol.2. Zone electrophoresis. Great Britain: Pitman Press; 1968. p. 369-383
13. González-Quevedo Monteagudo A, Fernández Carriera RA, León Ortiz MM, González García S, Vicente Valdés I. Electroforesis de proteínas del líquido cefalorraquídeo normal en niños y adultos. Rev Mex Neuroci 2008;9:242-247
14. Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G, et al. Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosc 2003;23:1949-1955 (Pubitemid 36314750)
15. Takeoka T, Shinohara Y, Furumi K, Mori K. Characteristic protein fractions of cerebrospinal fluid disc electrophoresis analysis. Brain Res 1980;198:147-156 (Pubitemid 10002680)
16. Douglas MR, Winer JB. Guillain-Barré syndrome and its treatment. Exp Rev Neurotherapeutics 2006;6:1569-1574
17. Burns TM. Guillain-Barré Syndrome. Semin Neurol 2008;28:152-167
18. Brettschneider J, Claus A, Kassubek J, Tumani H.Isolated bloodcerebrospinal fluid barrier dysfunction: Prevalence and associated diseases. J Neurol 2005;252:1067-1073 (Pubitemid 41355837)
19. Dorta, AJ, Reiber H. Teoría de la difusión molecular/flujo del líquido cefalorraquídeo. Rev Neurol 2004;39:564-569 (Pubitemid 39472015)
20. Matá S, Galli E, Amantini A, Pinto F, Sorbi S, Lolli F. Anti-ganglioside antibodies and elevated CSF IgG levels in Guillain-Barré Síndrome. Eur J Neurol 2006;13:153-160
21. Kanda T, Yamawaki M, Mizusawa H. Sera from Guillain-Barré patients enhance leakage in blood-nerve barrier model. Neurology 2003;60:301-306 (Pubitemid 36152027)
22. Créange A, Sharshar T, Planchenault T, Christov C, Poron F, Raphaël JC, et al. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome. Neurology 1999;53:1683-1691
23. Rosenberg GA. Matrix Metalloproteinases and neuroinflammation in Multiple Sclerosis. Neuroscientist 2002;8:586-595
24. Petzold A, Hinds N, Murray NM, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: A potential prognostic marker in Guillain- Barré syndrome. Neurology 2006;67:1071-1073 (Pubitemid 44454609)
25. Wanschitz J, Ehling R, Löscher WN, Künz B, Deisenhammer F, Kuhle J, et al. Intrathecal anti-alphaB-crystallin IgG antibody responses: Potential inflammatory markers in Guillain-Barré syndrome. J Neurol 2008;255:917-924
26. Yang YR, Liu SL, Qin ZY, Liu FJ, Qin YJ, Bai SM, et al. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain- Barré syndrome. Cell Mol Neurobiol 2008;28:737-744
27. Lehmensiek V, Süssmuth SD, Brettschneider J, Tauscher G, Felk S, Gillardon F, et al. Proteome analysis of cerebrospinal fluid in Guillain- Barré syndrome (GBS). J Neuroimmunol 2007;185:190-194 (Pubitemid 46497448)
28. Reiber H, Otto M, Trendelenburg C, Wormek A. Reporting cerebrospinal fluid data: Knowledge base and interpretation software. Clin Chem Lab Med 2001;39:324-332 (Pubitemid 32433333)
29. Seneviratne U. Guillain-Barré syndrome. Postgrad Med J 2000;76:774-82.
30. Hartung HP, van der Meché FG, Pollard JD. Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol 1998;11:497-513.
31. Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Progr Neurobiol 2001;64:109-127 (Pubitemid 32195409)